In this issue:
Efficacy of blinatumomab
Comparison of eBEACOPP and BrECADD
Safety and effectiveness of venetoclax plus cytarabine
Effects of dose-escalating mosunetuzumab
Optimal management for R/R LCBL
Risk of secondary tumours after CAR-T
Durability of ViPOR regimen
Addition of ibrutinib to AlloHSCT
Comparing imatinib and ponatinib
Azacitidine versus investigator’s-choice standard therapy
Please login below to download this issue (PDF)